28 October 2026 Sydney, Australia Securities Purchase Plan Results Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today announces the close of its...
Securities Purchase Plan Results
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Nyrada Inc. has announced the results of its Securities Purchase Plan, which raised funds before costs. The plan allowed eligible CDI holders to subscribe for new fully paid CDIs, with a maximum subscription value per holder. Nyrada will issue new CDIs and options to participants, with trading in the new CDIs set to commence shortly. The Chair expressed gratitude to CDI holders for their support, emphasizing the importance of this funding for the company's development efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Nyrada
- Quarterly Activities Report and Appendix 4C
- PROTECT-MI Phase IIa Clinical Trial Update No 3
- Nyrada Receives Positive FDA Feedback
- Attaching Options Prospectus
- Securities Purchase Plan Offer Booklet
Later from Nyrada
- PROTECT-MI Phase IIa Clinical Trial Update No 4
- Application for quotation of securities - NYR
- Change of Director's Interest Notice - JM
- Update - Proposed issue of securities - NYR
- Notice of Initial Substantial Holding - J Moore
Follow Nyrada into a list and get an email when it puts out news.
Follow Nyrada